CSL Limited (ASX:CSL)

Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee has a broad global perspective and understanding of long-term capital projects in the pharmaceutical industry, with proven health, safety, environment and corporate responsibility.

Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a Senior Advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry.  In 2009, he was made an Officer of the Order of Australia for service to business and commerce.

Paul is an accomplished global leader with diverse biotechnology experience across the industry. Prior to joining CSL, he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen where he was responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering.

With more than 30 years of experience, Paul also held various senior roles in R&D and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck.

Paul was elected to the National Academy of Engineering in 2020. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. Paul holds a B.S. in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering from Carnegie Mellon University. Paul McKenzie was appointed Chief Operating Officer in June 2019 and leads CSL’s global end-to-end operations organization and its accompanying strategy.

This role includes responsibility for CSL Plasma, manufacturing, quality, engineering, environment, health & safety, supply chain and procurement. Paul also has responsibility for the Seqirus business.

Dr Clark has significant executive and non-executive experience across a broad range of sectors including scientific research, health, investment banking and financial services, education and mining.  Through her roles, Dr Clark brings a broad strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance.

Dr Clark was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014.  Prior to joining CSIRO, she was a Director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including Vice President Technology and Vice President Health, Safety and Environment.

Professor Cuthbertson has over 35 years’ experience in medical research and biotech development with large biopharmaceutical companies and medical organisations.  He also has non-executive director experience.

Professor Cuthbertson joined CSL in April 1997 as the Director of Research. Prior to CSL, he was a Senior Scientist at Genentech Inc, a biotechnology company dedicated to pursuing ground-breaking science to discover and develop medicine for people with life-threatening diseases. After completing medical training at the University of Melbourne and PhD in Immunology at the Walter and Eliza Hall Institute in Australia, Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne.

Dr Daniels has over 30 years of experience in clinical development, medical affairs, commercialization and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018.

Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across a number of therapeutic areas including in Cardio-Vascular, Virology and Oncology. 

Dr. Daniels received Bachelor of Science and Medical Science degrees from Massachusetts Institute of Technology and his M.D. from Washington University, St. Louis. He trained in internal medicine at New York Hospital and rheumatology/immunology at UCSF.

Ms Hewson is a former investment banker with over 35 years’ experience in the finance sector. She was previously an Executive Director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long term non-executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management, and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009 Ms Hewson was made an Officer in the Order of Australia for her services to the broader community and to business.

Ms Hewson is currently a Director of Infrastructure SA. She is also a former Director of BHP Group, Stockland Group, BT Investment Management Limited, Westpac Banking Corporation, AGL Energy Limited, the Australian Gas Light Company, CSR Limited, AMP Limited, South Australian Water and the Economic Development Board of South Australia.

Ms Lewis is an experienced non-executive director serving on boards of ASX 100 companies since 2014.

Ms Lewis is a chartered accountant with extensive experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence.  Prior to becoming a Non-Executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner. In that role, she acted as lead auditor of a number of major Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs and debt/equity raisings. Ms Lewis has significant experience working with companies in the manufacturing, retail and industrial sectors. 

She is currently a Non-Executive Director at Nine Entertainment Co. Holdings Limited and Australia Pacific Airports Corporation Limited.

Ms McDonald has significant executive and non-executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance, and change management.

Ms McDonald is a former lawyer with over 30 years’ experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a Member of the Australian Takeovers Panel for nine years.

Ms Sorg has more than 35 years’ experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie’s US commercial operations, the company’s largest commercial business. She was a key leader in bringing a number of groundbreaking medicines to patients across Immunology, Oncology, Neuroscience and Eye Care.

Ms Sorg’s deep experience extends across biopharmaceutical industry and is recognised for her outstanding leadership and successfully building franchises and brands across therapeutic areas and segments.

Ms Sorg holds a Bachelor of Science (Pharmacy) from Purdue University, as well as postgraduate certifications from the University of Chicago Booth School of Management, and Harvard Business School. She is currently on the Dean’s Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global health care clients on business-critical strategies and decisions.

Ms Watkins brings deep experience to our Board through the executive and non-executive roles she has held across industries including manufacturing, agriculture, consumer goods, retail and financial services.  

Ms Watkins was most recently the Group Managing Director of ASX listed Coca-Cola Amatil Limited, where she was responsible for operations in Australia, New Zealand, Indonesia and across the South Pacific region. 

Ms Watkins holds a Bachelor of Commerce from the University of Tasmania, is a Fellow of the Institute of Chartered Accountants, the Financial Services Institute of Australasia, and the Australian Institute of Company Directors.  

Ms Mead was appointed Company Secretary and Head of Corporate Governance effective June 2018. Previously, she was the Company Secretary and a member of the Executive Leadership Team at Tabcorp Holdings Limited. Prior to that, Ms Mead was the Company Secretary at Asciano Limited, and earlier, Assistant Company Secretary at Telstra. Fiona began her career as a lawyer with law firm Ashurst.

Ms Mead is a fellow of the Chartered Governance Institute of Australia, Chartered Governance Professional and a Graduate member of the Australian Institute of Company Directors.